Media Releases
Download the media release
English (PDF 0.2 MB ) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)
Novartis ranked second in the 2021 Access to Medicine Index (ATMIndex), maintaining the same leading position as in 2018, in recognition of its long-standing efforts to improve …
- Full year net sales from continuing operations¹ up 3% (cc², +3% USD):
- Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)
- Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)
- Sandoz …
Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
- Full year net sales from continuing operations¹ up 3% (cc², +3% USD):
- Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)
- Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)
- Sandoz sales …
Sandoz officially certified as Global Top Employer 2021
- Top Employers Institute recognizes Sandoz for its exceptional employee offerings globally
- Third such annual certification for Sandoz underlines ongoing commitment to attract and keep best talent by building a great place to work
Basel, January 25, 2021 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded “Global Top Employer 2021” certification for the third year in a row. This year, Sandoz was one of only 16 Top Employers recognized for their outstanding HR …
COVID-19 was a catalyst for change in healthcare during 2020 – an accelerator for digital health.
2021 looks set to continue the revolution – exploiting ‘an explosion of interest, traction and scale’ in the potential for digital innovation to meet global healthcare needs.
In early 2020, as the virus spread exponentially, the world was forced to work virtually, where possible. Digital solutions were needed fast – not just to support remote-working, but to keep the very fabric of business, healthcare, education, and essential services in operation.
For Novartis and many …
- Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
- Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years
- Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by March 1, 2021
Basel, January 19, 2021 — Novartis and GSK today announced the …
Dear SMA community,
One year ago we launched a global Managed Access Program (MAP), the first for a one-time gene therapy, to make Zolgensma® (onasemnogene abeparvovec) available to eligible patients with spinal muscular atrophy (SMA) who are under the age of two in countries where Zolgensma has not received regulatory approval. Today we are pleased to share that we allocated 100 doses free-of-charge in 2020, and …
- Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1
- Currently there are limited approved therapies for patients with CSU, also known as chronic idiopathic urticaria (CIU)
- Breakthrough Therapy designation suggests ligelizumab has the potential to provide a substantial benefit over existing available treatments
- U.S. regulatory filing in CSU is anticipated in 2022 …
- Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
- Novartis secures development and commercialization rights in North America, Europe, and Japan
- Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
- Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial …